A potential breakthrough in HIV prevention has been announced, with a drug called lenacapavir showing promise in suppressing and preventing the virus. Researchers estimate that a generic version of the drug could be produced for as little as $40 per year, which is significantly cheaper than its current price tag of $42,250. The UNAids organization has hailed the development as "herald[ing] a breakthrough for HIV prevention" if made widely available.

Source: https://www.theguardian.com/global-development/article/2024/jul/23/hiv-aids-prevention-vaccine-lenacapavir-sunlenca-pharmaceuticals-gilead-generic-licensing